Ablynx N.v.

Frank Kamiel Delphina Verdonck

Erik Depla

Stephanie Staelens

Gerald Beste

Robert Hofmeister

Bjoern Hock

Christine Knuehl

Alisa K Waterman

Diane Van Hoorick

Sigrid Cornelis

Hilde Adi Pierrette Revets

Sigrid Godelieve Victor Cornelis

Francis Descamps

Daniel Janssen

Veerle Delanote

Mark Edward Labadia

Ann Mikhail

The present invention relates to immunoglobulins that specifically bind Kv1.3 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Kv1.3.

KV1.3 binding immunoglobulins

The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as 'amino acid sequences of the invention', 'compounds of the invention', and &#x201c;polypeptides of the invention&#x201d;, respectively). The disclosure also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as &#x201c;nucleic acids of the invention&#x201d; or &#x201c;nucleotide sequences of the invention&#x201d;); to methods forpreparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein.

Biological materials related to HER3

The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as 'amino acid sequences of the invention', 'compounds of the invention', and &#x201c;polypeptides of the invention&#x201d;, respectively). The disclosure also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as &#x201c;nucleic acids of the invention&#x201d; or &#x201c;nucleotide sequences of the invention&#x201d;); to methods for 10 preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein.

Growing community of inventors

Sint-Gillis-Waas, Belgium

Frank Kamiel Delphina Verdonck